Get started
Author

Martin Heuschkel

Observed names: Heuschkel, Martin, M Heuschkel, M. Heuschkel
ORCID: 0009-0003-9079-2186
Observed ORCID: 0009-0003-9079-2186
OpenAlex ID: A5012908316
German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
2016 · Kambiz Rahbar, Hojjat Ahmadzadehfar, et al. · Journal of Nuclear Medicine · 833
PDF
First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer
2019 · Jens Kurth, Bernd Joachim Krause, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 143
Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom
2016 · Wolfgang Fendler, Clemens Kratochwil, et al. · Nuklearmedizin - NuclearMedicine · 110
Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging
2016 · Sascha Nitsch, Oliver W. Hakenberg, et al. · Journal of Nuclear Medicine · 32
PDF
Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
2021 · Jens Kurth, Martin Heuschkel, et al. · Cancers · 27
PDF
Preclinical Comparison of the 64 Cu- and 68 Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [ 68 Ga]Ga-AMTG PET/CT
2023 · Lena Koller, Markus Joksch, et al. · Journal of Nuclear Medicine · 25
PDF
Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate
2018 · Anastassia Löser, Sarah M. Schwarzenböck, et al. · Nuclear Medicine Communications · 25
Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study
2024 · Siddhartha Baxi, Saima Vohra, et al. · Journal of Nuclear Medicine · 14
PDF
[18F]FDG PET/CT for assessing inguinal lymph nodes in patients with penile cancer - correlation with histopathology after inguinal lymphadenectomy.
2018 · Desiree L Dräger, Martin Heuschkel, et al. · PubMed · 14
Topical 188Re Ionizing Radiation Therapy Exerts High Efficacy in Curing Nonmelanoma Skin Cancer
2023 · Julia K. Tietze, Martin Heuschkel, et al. · Clinical Nuclear Medicine · 13
First-in-Human Serum Stability Studies of [ 177 Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy
2025 · Veronika Felber, Nadine Holzleitner, et al. · Journal of Nuclear Medicine · 12
PDF
Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival
2021 · Jens Kurth, Justus Kretzschmar, et al. · Nuclear Medicine Communications · 12
Safety and efficacy of Holmium-166 selective internal radiotherapy of primary and secondary liver cancer confirmed by real-world data
2024 · Victor Schulze-Zachau, Gontran Verset, et al. · Frontiers in Oncology · 9
PDF
GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals
2022 · Jens Kurth, Madlin Potratz, et al. · Nuklearmedizin - NuclearMedicine · 9
Efficacy, Safety, and Patient Reported Outcomes of Rhenium-Skin Cancer Therapy for Non-Melanoma Skin Cancer: 1-Year Results from the EPIC-Skin Study
2025 · Giuseppe Cardaci, Siddhartha Baxi, et al. · Advances in Radiation Oncology · 7
90 Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis
2026 · Helena Lanzafame, Ilektra A. Mavroeidi, et al. · Journal of Nuclear Medicine · 6
Patient-Orientated Evaluation of Treatment of Non-Melanoma Skin Cancer with Rhenium-188 Compared to Surgery
2024 · Maila I. C. Krönert, Sarah M. Schwarzenböck, et al. · Healthcare · 6
Abstract CT112: Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of FXX489 ([177Lu]Lu-NNS309) in patients with pancreatic, lung, breast and colorectal cancers
2025 · Ravit Geva, Daniel Juneau, et al. · Cancer Research · 2
Semi-automated Analysis of Ventilation-Perfusion Single-Photon Emission Tomography in the Diagnosis of Pulmonary Embolism – Does it add extra value?
2020 · Jens Kurth, Johannes Uhländer, et al. · Nuklearmedizin - NuclearMedicine · 1
[90Y]Y-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer - Post-therapeutic kidney and bone marrow dosimetry for individualized therapy
2020 · Jens Kurth, Bernd J. Krause, et al. · Journal of Nuclear Medicine · 1
Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: A sub-study of the VISION trial.
2020 · Jens Kurth, Ken Herrmann, et al. · Journal of Clinical Oncology · 1
Die Cholin-PET/CT für Diagnostik, Staging und Restaging des Prostatakarzinoms
2015 · M. Heuschkel, B. Krause, et al. · Der Nuklearmediziner · 1
188Rhenium skin cancer therapy: Two–year efficacy, safety and patient reported outcomes from the prospective, multicentre, phase IV, EPIC-skin study in non-melanoma skin cancer
2026 · Siddhartha Baxi, Giuseppe Cardaci, et al. · EANM Innovation
PDF
Evaluation of gastrin-releasing peptide receptor- radioligand [⁶⁸Ga]Ga-AMTG for imaging of glioblastoma multiforme grade IV: in vitro and in ovo studies
2026 · A Dańko, K Tesch, et al. · Nuklearmedizin - NuclearMedicine
Rhenium-188 skin cancer therapy: two-year efficacy and safety from a prospective multicenter phase IV study with dermatology-directed assessment of skin findings
2026 · S. Shumack, V.A. Patel, et al. · EJC Skin Cancer
PDF
Works count: 42
Citation count: 1,314
H-index: 12
I10-index: 13
Year
Topic
Type